Skip to main content

Scabies

7
Pipeline Programs
9
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
3
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Medpace
MedpaceCINCINNATI, OH
1 program
1
Spinosad TopicalPhase 41 trial
Active Trials
NCT05310734Unknown50Est. Mar 2026
ParaPRO
ParaPROIN - Carmel
2 programs
2
spinosad topical suspension, 0.9%Phase 31 trial
spinosad topical suspension, 0.9%Phase 31 trial
Active Trials
NCT02485717Completed291Est. Jun 2018
NCT02485704Completed280Est. Aug 2018
Dr. Reddy's Laboratories
1 program
1
PermethrinPhase 31 trial
Active Trials
NCT02572986Completed250Est. Aug 2016
Vyne Therapeutics
Vyne TherapeuticsIsrael - Ness Ziona
1 program
1
Permethrin Foam 4%Phase 21 trial
Active Trials
NCT02094716Completed130Est. Dec 2014
Combined Therapeutics
2 programs
2
Ivermectin TabletsPhase 11 trial
PermethrinPhase 11 trial
Active Trials
NCT05362513Completed100Est. Nov 2021
NCT05862701Completed60Est. Sep 2022
Medica Corp
Medica CorpMA - Bedford
1 program
data collectionN/A1 trial
Active Trials
NCT07305961Completed1,332Est. Dec 2025
IQVIA
IQVIADURHAM, NC
1 program
Spinosad TopicalPHASE_4
Cipher Pharmaceuticals
Cipher PharmaceuticalsON - Mississauga
1 program
Spinosad TopicalPHASE_4
Inotiv
InotivWEST LAFAYETTE, IN
1 program
Spinosad TopicalPHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MedpaceSpinosad Topical
ParaPROspinosad topical suspension, 0.9%
ParaPROspinosad topical suspension, 0.9%
Dr. Reddy's LaboratoriesPermethrin
Vyne TherapeuticsPermethrin Foam 4%
Combined TherapeuticsPermethrin
Combined TherapeuticsIvermectin Tablets
Medica Corpdata collection

Clinical Trials (8)

Total enrollment: 2,493 patients across 8 trials

NCT05310734MedpaceSpinosad Topical

PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies

Start: Mar 2022Est. completion: Mar 202650 patients
Phase 4Unknown
NCT02485704ParaPROspinosad topical suspension, 0.9%

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

Start: May 2017Est. completion: Aug 2018280 patients
Phase 3Completed
NCT02485717ParaPROspinosad topical suspension, 0.9%

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

Start: May 2017Est. completion: Jun 2018291 patients
Phase 3Completed
NCT02572986Dr. Reddy's LaboratoriesPermethrin

A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies

Start: Sep 2015Est. completion: Aug 2016250 patients
Phase 3Completed
NCT02094716Vyne TherapeuticsPermethrin Foam 4%

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

Start: Apr 2014Est. completion: Dec 2014130 patients
Phase 2Completed
NCT05862701Combined TherapeuticsPermethrin

Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies

Start: Mar 2022Est. completion: Sep 202260 patients
Phase 1Completed
NCT05362513Combined TherapeuticsIvermectin Tablets

Comparative Study Between Topical Permethrin 5% and Oral Ivermectin for the Treatment of Scabies

Start: Jun 2021Est. completion: Nov 2021100 patients
Phase 1Completed
NCT07305961Medica Corpdata collection

National Study on the Epidemiology and Effectiveness of Therapies in the Treatment of Scabies

Start: Jan 2025Est. completion: Dec 20251,332 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.